the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
#cagrilintide 2025-09-03
Wednesday35 messages9 participantstimes are UTC
Highlights from this day
- lisbon_lot — noticed something around week 4 on monotherapy, well after i had given up expecting to 21:26
- lisbon_lot — weekly for me, same day every week, no reason beyond habit 21:35
- tarpit_tam — slightly off topic but stopped for 8 months and the fullness went within a fortnight of the last dose 21:38
- chlorhex — while im here the fullness thing is the part people describe differently, food stops being interesting rather than repellent 22:34
- cross_border_cam — is the weekly schedule the same here 23:02
noticed something around week 4 on monotherapy, well after i had given up expecting to
🔥10📉11
underwhelming honestly
cagrisema thats it
weekly for me, same day every week, no reason beyond habit
janoshik-c-4402.pdf
2 pages · 389 KB · not retained in the public archive
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake
slightly off topic but stopped for 8 months and the fullness went within a fortnight of the last dose
🧪5⚠️4🔥4
anyone got two PeptideMeter results on the same SWB lot for this
monotherapy was underwhelming for me and i say that as someone who wanted it to work
coming back to this amylin analogue, so its not a GLP-1 at all right
held mine a while
i keep the two on separate days so if something goes wrong i have a chance of knowing which
you cannot tell which of the two is doing what in a combination and i stopped pretending i could
is 2.4 the number for this too or am i confusing compounds
nobody should copy my schedule, im describing it because people asked what a slow ramp looks like, thats one data point
genuine question the slower titration in here is community habit as much as anything, the trials had their own schedule
monotherapy did work for me, just slower and smaller than i expected
update on the earlier thing the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair
the fullness effect hasnt faded over 3 months, unlike my semaglutide appetite curve
i titrated over twice as many weeks as i did on semaglutide and that was right for me
titrating dead slow
the reason nausea reads differently is timing, mine arrived on the second day rather than the first
two Janoshik results on the same CPC lot came back 99.2 and 98.6, closer than i expected
while im here the fullness thing is the part people describe differently, food stops being interesting rather than repellent
👍3🎉2❤️1
held at 1 for 6 months on monotherapy before i touched it again
👍5
fullness rather than nausea
separate days
📉1
for the archive amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist
dosing them on different days made no difference i could detect
cant separate them
sorry to jump in did the combination change your GI compared to the GLP-1 alone
👍2❤️1🧪1
is the weekly schedule the same here
🧪15📉1
thats the phase 3 one
slightly off topic but how many weeks before you noticed anything on monotherapy
📉6
Inter-lab diff for lot B-0114: 98.1% vs 97.4%. Within expected range.